Literature DB >> 16732691

Glaucoma medications: use and safety in the elderly population.

Elliott Kanner1, James C Tsai.   

Abstract

As with many diseases, glaucoma increases in frequency in older populations, and is very often encountered in patients taking multiple medications. While the exact mechanism of glaucomatous optic neuropathy (GON) is not known, intraocular pressure (IOP) is thought to be central to the process, and reducing IOP is the only known effective treatment. The newer definition of glaucoma is an IOP-sensitive optic neuropathy. While large, controlled studies have indicated that reducing IOP will slow the progression of disease, the contributions of other conditions and medications have not been adequately studied. As the adverse effect profiles of medical therapies for glaucoma have improved, use of these agents has increased greatly. This has resulted in a large number of older patients taking glaucoma medications. Since topical medications can easily be overlooked in a medical history, and are for the most part well tolerated, systemic complications from these agents can be missed. In addition to being a common disease requiring treatment, glaucoma is also a model system for other degenerative diseases, and many of the concepts originally developed in relation to neurodegenerative diseases such as Alzheimer's disease are under investigation for glaucoma. These include approaches targeted towards neuroprotection and excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732691     DOI: 10.2165/00002512-200623040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  79 in total

1.  Aqueous humor dynamics in the aging human eye.

Authors:  C B Toris; M E Yablonski; Y L Wang; C B Camras
Journal:  Am J Ophthalmol       Date:  1999-04       Impact factor: 5.258

Review 2.  Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment.

Authors:  Paul J Lama
Journal:  Am J Ophthalmol       Date:  2002-11       Impact factor: 5.258

Review 3.  Factors influencing blood flow in the optic nerve head.

Authors:  S S Hayreh
Journal:  J Glaucoma       Date:  1997-12       Impact factor: 2.503

4.  Experimental aqueous perfusion in enucleated human eyes. Results after obstruction of Schlemm's canal.

Authors:  V L Jocson; M L Sears
Journal:  Arch Ophthalmol       Date:  1971-07

5.  Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.

Authors:  J S Schuman
Journal:  Ophthalmology       Date:  2000-06       Impact factor: 12.079

6.  Association between intraocular pressure peaks and progression of visual field loss.

Authors:  R C Zeimer; J T Wilensky; D K Gieser; M A Viana
Journal:  Ophthalmology       Date:  1991-01       Impact factor: 12.079

7.  Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.

Authors:  E Yoles; L A Wheeler; M Schwartz
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-01       Impact factor: 4.799

8.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

9.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey.

Authors:  A Sommer; J M Tielsch; J Katz; H A Quigley; J D Gottsch; J Javitt; K Singh
Journal:  Arch Ophthalmol       Date:  1991-08

Review 10.  Applying an evidence-based approach to the management of patients with ocular hypertension: evaluating and synthesizing published evidence.

Authors:  Anne L Coleman; Kuldev Singh; Richard Wilson; George A Cioffi; David S Friedman; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

View more
  7 in total

1.  Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics.

Authors:  Luciano Quaranta; Elena Biagioli; Francesca Galli; Davide Poli; Eliana Rulli; Ivano Riva; Lital Hollander; Andreas Katsanos; Antonio Longo; Maurizio G Uva; Valter Torri; Robert N Weinreb
Journal:  Adv Ther       Date:  2016-06-16       Impact factor: 3.845

2.  Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension.

Authors:  Misha F Syed; Emma Kr Loucks
Journal:  Clin Ophthalmol       Date:  2011-09-08

3.  Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation.

Authors:  Arsham Sheybani; Rachel Scott; Thomas W Samuelson; Malik Y Kahook; Daniel I Bettis; Iqbal Ike K Ahmed; J David Stephens; Delaney Kent; Tanner J Ferguson; Leon W Herndon
Journal:  Ophthalmol Ther       Date:  2019-11-15

4.  5-(Sulfamoyl)thien-2-yl 1,3-oxazole inhibitors of carbonic anhydrase II with hydrophilic periphery.

Authors:  Stanislav Kalinin; Alexander Kovalenko; Annika Valtari; Alessio Nocentini; Maxim Gureev; Arto Urtti; Mikhail Korsakov; Claudiu T Supuran; Mikhail Krasavin
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

5.  Antioxidant, Antidiabetic, Anticholinergic, and Antiglaucoma Effects of Magnofluorine.

Authors:  Lokman Durmaz; Hatice Kiziltas; Leyla Guven; Hasan Karagecili; Saleh Alwasel; İlhami Gulcin
Journal:  Molecules       Date:  2022-09-11       Impact factor: 4.927

Review 6.  Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.

Authors:  F Honrubia; J García-Sánchez; V Polo; J M Martínez de la Casa; J Soto
Journal:  Br J Ophthalmol       Date:  2008-11-19       Impact factor: 4.638

Review 7.  Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review.

Authors:  Olga Cegielska; Paweł Sajkiewicz
Journal:  Polymers (Basel)       Date:  2019-10-24       Impact factor: 4.329

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.